FindTrial
Sign In

Evaluating Adherence to Pharmacologic Treatment in Real-world Clinical Practice: A Comprehensive Analysis

Anti osteoporotic treatment :Assessing the adherence to pharmacologic treatment in clinical practice - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061240
Enrollment
385
Registered
2024-01-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M800- Age-related osteoporosis with current pathological fracture Health Condition 2: M800- Age-related osteoporosis with current pathological fracture Health Condition 3: E88- Other and unspecified metabolic disorders

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Stavya Spine Hospital and Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: DEXA proven osteoporotic patients (T score less than-2.5) Patients with history of fragility fractures Patients consenting for participation in the study

Exclusion criteria

Exclusion criteria: Patients not fulfilling inclusion criteria. Patients not consenting for participation.

Design outcomes

Primary

MeasureTime frame
1.Adherence rates to the drug regimens prescribed 2.In case of defaulters, reasons for discontinuation of the drug Timepoint: patients will be followed up for a period of 2 years from the point of enrollment in the study.The patients will be scheduled for follow up at 3,6,12,18 and 24 months.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Bharat R Dave

Stavya Spine Hospital And Research Institute

brd_172@yahoo.com9825019913

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 27, 2026